Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Staar Surgical ( (STAA) ) has shared an update.
On June 25, 2025, STAAR Surgical announced the appointment of Deborah Andrews as Chief Financial Officer, effective immediately. Andrews, who previously served as interim CFO since March 2025 and held various roles at STAAR, brings extensive experience and is expected to enhance financial and operational rigor. Additionally, STAAR established a new Capital Stewardship Committee to guide financial strategies, chaired by Lilian Y. Zhou, aiming to improve capital management and shareholder value. The company also restructured its investor relations function, resulting in the departure of Brian Moore, Vice President of Investor Relations and Corporate Development.
The most recent analyst rating on (STAA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The overall stock score reflects significant challenges in financial performance with declining revenues and negative margins as the most impactful factors. While corporate events and strategic initiatives provide a positive outlook, technical indicators and valuation metrics caution about potential risks. The company needs to address operational and profitability issues to improve investor sentiment.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical is a global leader in implantable phakic intraocular lenses, specializing in vision correction solutions that reduce or eliminate the need for glasses or contact lenses. The company, headquartered in Lake Forest, California, has been dedicated to ophthalmic surgery since 1982 and has sold over 3 million Implantable Collamer® Lenses in more than 75 countries.
Average Trading Volume: 899,303
Technical Sentiment Signal: Sell
Current Market Cap: $826.1M
For a thorough assessment of STAA stock, go to TipRanks’ Stock Analysis page.